Skip to menu Skip to content Skip to footer
Professor Maher Gandhi
Professor

Maher Gandhi

Email: 

Overview

Background

Maher Gandhi received his medical degree in the UK in 1989, and then trained as a haematologist, including a Fellowship in malignant haematology at Princess Margaret Cancer Centre, Toronto. He was awarded a PhD in immunology at Cambridge University under Patrick Sissons. In 2003 he moved to Brisbane, and works as a Senior Staff Specialist (Pre-Eminent Status) in the Haematology / Oncology Department of the Princess Alexandra Hospital. He leads his own laboratory group and has established an international reputation studying immunity and identification of novel biomarkers in lymphoma, with continuous NHMRC funding since 2005. He was Chair of Laboratory Sciences for the Australasian Leukaemia and Lymphoma Group between 2010-2016, won the prestigious Australian Society of Medical Research Clinical Research Award in 2010 and in 2012 took up the inaugural John McCaffrey Cancer Council of Queensland / Office of Health and Medical Research Clinical Research Fellowship. Between 2011-2014 he was privileged to serve as Chair of the Metro South Human Research Ethics Committee. In 2013 he was appointed Professor of Experimental Haematology, University of Queensland, based at the Translational Research Institute, in 2014 became the inaugural Leukaemia Foundation Chair of Blood Cancer Research at the University of Queensland Diamantina Institute, and was appointed Diamantina Cancer Program Head in 2016. In 2018 to current, he moved to Mater Research, where he is Executive Director, as well Director of MRI-UQ.

Availability

Professor Maher Gandhi is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Medicine Surgery, University of Aberdeen
  • Doctor of Philosophy, University of Cambridge

Research interests

  • Lymphoma

  • Immunotherapy

  • Biomarkers

Research impacts

The research of the Blood Cancer Research Laboratory aims to understand the basis of lymphoma; to devise new treatments which are less toxic and more effective; to establish new biomarkers which will help determine the most effective treatment strategies and to monitor response and relapse and understand the development of lymphomas. The group has a strong emphasis on patient material, which it obtains from international and national clinical collaborators. Lymphomas studied include Hodgkin Lymphoma, PTLD, Diffuse Large B-cell Lymphoma, Follicular Lymphoma and virus associated lymphomas. We utilise a broad range of approaches including genomics, molecular and cellular biology techniques and functional immunoassays. Several of our studies are linked with the Australasian Leukaemia and Lymphoma Group.

The Mater Foundation, the Leukaemia Foundation, and the Brisbane Girls Grammar School Kirsten Jack Memorial Fund are thanked for their kind support.

Works

Search Professor Maher Gandhi’s works on UQ eSpace

211 works between 1993 and 2024

61 - 80 of 211 works

2019

Journal Article

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

Tobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David, Bell, Stephen, Dunduru, Chengetai, Gallo, James, Tsang, Erica S., Tan, Xuan, Wong, Jonathan, Pearce, Jessica, Campbell, Robert, Tneh, Shao, Shorten, Sophie, Ng, Melissa, Cochrane, Tara, Tam, Constantine S., Abro, Emad, Hawkes, Eliza, Hodges, Georgina, Kansara, Roopesh, Talaulikar, Dipti, Gilbertson, Michael, Johnston, Anna M., Savage, Kerry J., Villa, Diego, Morris, Kirk, Ratnasingam, Sumi ... Hapgood, Greg (2019). Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. Blood Advances, 3 (19), 2804-2811. doi: 10.1182/bloodadvances.2019000458

Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance

2019

Journal Article

The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma

Keane, Colm, Tobin, Joshua, Gunawardana, Jay, Francis, Santiyagu, Gifford, Grace, Gabrielli, Sara, Gill, Anthony, Stevenson, William, Talaulikar, Dipti, Gould, Clare, Jain, Sanjiv, Birch, Simone, Hertzberg, Mark and Gandhi, Maher K. (2019). The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. European Journal of Haematology, 103 (3) ejh.13274, 200-207. doi: 10.1111/ejh.13274

The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma

2019

Journal Article

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Barraclough, Allison, Alzahrani, Musa, Ettrup, Marianne Schmidt, Bishton, Mark, van Vliet, Chris, Farinha, Pedro, Gould, Clare, Birch, Simone, Sehn, Laurie H., Sovani, Vishakha, Ward, Mitchell Steven, Augustson, Bradley, Biccler, Jorne, Connors, Joseph M., Scott, David W., Gandhi, Maher K., Savage, Kerry J., El-Galaly, Tarec, Villa, Diego and Cheah, Chan Yoon (2019). COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances, 3 (13), 2013-2021. doi: 10.1182/bloodadvances.2019000251

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

2019

Journal Article

Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions

Stannard, Kimberley A., Lemoine, Sébastien, Waterhouse, Nigel J., Vari, Frank, Chatenoud, Lucienne, Gandhi, Maher K., Martinet, Ludovic, Smyth, Mark J. and Guillerey, Camille (2019). Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions. Blood Advances, 3 (11), 1681-1694. doi: 10.1182/bloodadvances.2018030676

Human peripheral blood DNAM-1neg NK cells are a terminally differentiated subset with limited effector functions

2019

Conference Publication

EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy

Gandhi, M.K., Hoang, T., Tobin, J.W., Law, S.C., Talaulikar, D., Jain, S., Vari, F., Murigneux, V., Fink, L., Gunawardana, J., Gould, C., Oey, H., Delecluse, S., Trappe, R.U., Merida de Long, L., Sabdia, M.B., Bhagat, G., Hapgood, G., Blyth, E., Clancy, L., Casey, J., Wight, J., Hawkes, E. and Keane, C. (2019). EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy. 15th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18–22 June 2019. Oxford, United Kingdom: John Wiley & Sons. doi: 10.1002/hon.91_2629

EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy

2019

Journal Article

Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions

Lees, Charlotte, Keane, Colm, Gandhi, Maher K. and Gunawardana, Jay (2019). Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. British Journal of Haematology, 185 (1), 25-41. doi: 10.1111/bjh.15778

Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions

2019

Journal Article

Simple, rapid and inexpensive typing of common HLA class I alleles for immunological studies

Law, Soi Cheng, Haigh, Oscar L., Walpole, Carina M., Keane, Colm, Miles, John, Gandhi, Maher K., Radford, Kristen J. and Steptoe, Raymond J. (2019). Simple, rapid and inexpensive typing of common HLA class I alleles for immunological studies. Journal of Immunological Methods, 465, 72-76. doi: 10.1016/j.jim.2018.12.002

Simple, rapid and inexpensive typing of common HLA class I alleles for immunological studies

2019

Conference Publication

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Gould, Clare, Keane, Colm, Murigneux, Valentine, Oey, Harald, Ellis, Jonathan, Birch, Simone, Gunawardana, Jay, Talaulikar, Dipti, Hertzberg, Mark S., Jones, Kimberley and Gandhi, Maher K. (2019). B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL. ASH Annual Meeting, Orlando, FL, United States, 7-10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-126537

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

2018

Journal Article

Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker

Sina, Abu Ali Ibn, Carrascosa, Laura G., Liang, Ziyu, Grewal, Yadveer S., Wardiana, Andri, Shiddiky, Muhammad J. A., Gardiner, Robert A., Samaratunga, Hemamali, Gandhi, Maher K., Scott, Rodney J., Korbie, Darren and Trau, Matt (2018). Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker. Nature Communications, 9 (1) 4915, 4915. doi: 10.1038/s41467-018-07214-w

Epigenetically reprogrammed methylation landscape drives the DNA self-assembly and serves as a universal cancer biomarker

2018

Conference Publication

A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial

Abro, Emad Uddin, Law, Soi C., Keane, Colm, Birch, Simone, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Johnson, Peter, Trotman, Judith, Berkahn, Leanne, Fulham, Michael, Anderson, Richard A., Saunderson, Anne L., Gunawardana, Jay, Cross, Donna, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Law, W. P., Gill, Devinder and Gandhi, Maher K. (2018). A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial. 60th ASH Annual Meeting, San Diego, CA United States, 1-4 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-112008

A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial

2018

Journal Article

Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large b-cell lymphoma

Cui, Qingyan, Vari, Frank, Cristino, Alexandre S., Salomon, Carlos, Rice, Gregory E., Sabdia, Muhammed B., Guanzon, Dominic, Palma, Carlos, Mathew, Marina, Talaulikar, Dipti, Jain, Sanjiv, Han, Erica, Hertzberg, Mark S., Gould, Clare, Crooks, Pauline, Thillaiyampalam, Gayathri, Keane, Colm and Gandhi, Maher K. (2018). Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large b-cell lymphoma. Oncotarget, 9 (78), 34644-34657. doi: 10.18632/oncotarget.26141

Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large b-cell lymphoma

2018

Journal Article

A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival

Keane, Colm, Tobin, Joshua, Talaulikar, Dipti, Green, Michael, Crooks, Pauline, Jain, Sanjiv and Gandhi, Maher (2018). A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. OncoTarget, 9 (34), 23620-23627. doi: 10.18632/oncotarget.25306

A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival

2018

Conference Publication

Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

Keane, Colm, Law, Soi C., Gould, Clare, Francis, Santiyagu, Abro, Emad Uddin, Tobin, Joshua W. D., Birch, Simone, Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Talaulikar, Dipti, Gill, Anthony, Jain, Sanjiv, Cross, Donna, Hernadez, Annette, Halliday, Sarah-Jane, Bird, Robert, Hertzberg, Mark and Gandhi, Maher K. (2018). Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, United States, 1-4 December 2018. Washington, DC, Untied States: American Society of Hematology. doi: 10.1182/blood-2018-99-112830

Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

2018

Conference Publication

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

Tobin, J., Keane, C., Mollee, P., Birch, S., Gould, C., Gunawardana, J., Hoang, T., Savarimuthu, S., Ma, T., Li, L., Murigneux, V. , Fink, L., Matigian, N. and Gandhi, M. K. (2018). The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma. RACP Congress 2018, Disruption for Healthy Futures, Sydney, NSW Australia, 14–16 May 2018. Hoboken, NJ United States: Wiley. doi: 10.1111/imj.2_13826

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

2018

Conference Publication

Outcomes of Stages I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance

Tobin, Joshua W. D., Rule, Gabrielle, Colvin, Katherine, Calvente, Lourdes, Hodgson, David C., Dunduru, Chengetai, Bell, Stephen, Gallo, James, Tsang, Erica, Tan, Xuan, Pearce, Jessica, Wong, Jonathan, Campbell, Robert, Tneh, Shao Yang, Shorten, Sophie, Ng, Melissa Liet Hing, Darch, Jacob, Cochrane, Tara, Tam, Constantine S., Abro, Emad Uddin, Hawkes, Eliza, Hodges, Georgina, Talaulikar, Dipti, Gilbertson, Michael P., Johnson, Anna, Kansara, Roopesh R., Villa, Diego, Savage, Kerry J., Morris, Kirk Lachlan ... Hapgood, Greg (2018). Outcomes of Stages I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-114097

Outcomes of Stages I and II Follicular Lymphoma in the Era of 18F-FDG PET-CT Staging: An International Collaborative Study from the Australian Lymphoma Alliance

2018

Journal Article

B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity

McKee, Sara J., Tuong, Zewen K., Kobayashi, Takumi, Doff, Brianna L., Soon, Megan S. F ., Nissen, Michael, Lam, Pui Yeng, Keane, Colm, Vari, Frank, Moi, Davide, Mazzieri, Roberta, Leggatt, Graham, Gandhi, Maher K. and Mattarollo, Stephen R. (2018). B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity. OncoImmunology, 7 (2) e1393599, e1393599. doi: 10.1080/2162402X.2017.1393599

B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity

2018

Conference Publication

The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma

Gunawardana, Jay, Bednarska, Karolina, Law, Soi C., Lee, Justina, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Birch, Simone, Keane, Colm and Gandhi, Maher K. (2018). The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego CA, United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-115836

The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma

2017

Conference Publication

The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma

Tobin, Joshua W. D., Keane, Colm, Mollee, Peter, Birch, Simone, Gould, Clare, Gunawardana, Jay, Hoang, Thanh , Ma, Ti, Abro, Emad Uddin, Shanavas, Mohamed, Yoo, Hyung, Li, Li, Scuffham, Paul, Murigneux, Valentine, Fink, Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu and Gandhi, Maher K. (2017). The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.V130.Suppl_1.728.728

The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma

2017

Journal Article

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

Hertzberg, Mark, Gandhi, Maher K. , Trotman, Judith, Butcher, Belinda, Taper, John, Johnston, Amanda, Gill, Devinder, Ho, Shir-Jing, Cull, Gavin, Fay, Ketih, Chong, Geoff, Grigg, Andrew, Lewis, Ian D. , Milliken, Sam, Renwick, William, Hahn, Uwe, Filshie, Robin, Kannourakis, George, Watson, Anne-Marie, Warburton, Pauline, Wirth, Andrew, Seymour, John F. , Hofman, Michael S. and Hicks, Rodney J. (2017). Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. Haematologica, 102 (2), 356-363. doi: 10.3324/haematol.2016.154039

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

2017

Conference Publication

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

Shanavas, Mohamed, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Tobin, Joshua W. D., Mathews, Marina, Francis, Santiyagu, Vari, Frank, Gandhi, Maher K. and Keane, Colm (2017). The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

Funding

Past funding

  • 2019 - 2020
    Indolent Lymphoma: Establishing a prognostic score fit for the modern era
    The Leukaemia Foundation of Australia Limited
    Open grant
  • 2018 - 2019
    A novel immunotherapy strategy for lymphoma using artificial microRNA gene targeting
    Metro South Hospital and Health Service
    Open grant
  • 2017 - 2019
    Pre-clinical studies of anti-LAG3 in lymphoma
    Bristol-Myers Squibb Pharmaceuticals Pty Limited
    Open grant
  • 2017
    Improving the evidence base for resource allocation in indolent lymphoma
    Gilead Australia Fellowship
    Open grant
  • 2016 - 2018
    Prognosticator for Follicular lymphoma (FL) and Mantle celly lymphoma (MCL)
    Research Donation Generic
    Open grant
  • 2016 - 2017
    Blood biomarkers in Hodgkin Lymphoma
    PA Research Foundation NHMRC Infrastructure Support
    Open grant
  • 2016
    Marshaling NK-cells in the fight against blood cancers: a novel approach
    PA Research Foundation NHMRC Near Miss Grant
    Open grant
  • 2015 - 2016
    Funding Assistance for Gandhi laboratory
    Metro South Hospital and Health Service
    Open grant
  • 2015 - 2016
    Using single-cell transcriptomics to define T-cell tolerance in EBV+ lymphoma
    PA Research Foundation
    Open grant
  • 2014 - 2018
    Leukaemia Foundation Queensland Chair in Blood Cancer Research (2014-2019)
    Leukaemia Foundation
    Open grant
  • 2014 - 2017
    Circulating Biomarkers in advanced classical Hodgkin Lymphoma
    NHMRC Project Grant
    Open grant
  • 2013 - 2014
    Monocytic myeloid derived suppressor cells and antiCD20-antibody dependent cellular cytotoxicity in diffuse large B-cell lymphoma (Cancer Council Queensland grant administered by PAH)
    Metro South Hospital and Health Service
    Open grant

Supervision

Availability

Professor Maher Gandhi is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Professor Maher Gandhi directly for media enquiries about:

  • Biomarkers
  • Immunotherapy
  • Lymphoma

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au